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Abstract: Gestational diabetes (GDM) increases the risk of pregnancy complications. However, these
risks are not the same for all affected women and may be mediated by inter-related factors including
ethnicity, body mass index and gestational weight gain. This study was conducted to identify,
compare, and critically appraise prognostic prediction models for pregnancy complications in women
with gestational diabetes (GDM). A systematic review of prognostic prediction models for pregnancy
complications in women with GDM was conducted. Critical appraisal was conducted using the
prediction model risk of bias assessment tool (PROBAST). Five prediction modelling studies were
identified, from which ten prognostic models primarily intended to predict pregnancy complications
related to GDM were developed. While the composition of the pregnancy complications predicted
varied, the delivery of a large-for-gestational age neonate was the subject of prediction in four studies,
either alone or as a component of a composite outcome. Glycaemic measures and body mass index
were selected as predictors in four studies. Model evaluation was limited to internal validation in
four studies and not reported in the fifth. Performance was inadequately reported with no useful
measures of calibration nor formal evaluation of clinical usefulness. Critical appraisal using PROBAST
revealed that all studies were subject to a high risk of bias overall driven by methodologic limitations
in statistical analysis. This review demonstrates the potential for prediction models to provide an
individualised absolute risk of pregnancy complications for women affected by GDM. However,
at present, a lack of external validation and high risk of bias limit clinical application. Future model
development and validation should utilise the latest methodological advances in prediction modelling
to achieve the evolution required to create a useful clinical tool. Such a tool may enhance clinical
decision-making and support a risk-stratified approach to the management of GDM. Systematic
review registration: PROSPERO CRD42019115223.
Keywords: gestational diabetes; prediction; risk; prognosis; pregnancy complications; large-for-
gestational age; neonatal hypoglycaemia; pre-eclampsia; shoulder dystocia; systematic review
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1. Introduction
Gestational diabetes (GDM) affects 7–20% of pregnancies and confers an increased risk of pregnancy
complications with health consequences for both mother and baby. These risks are related to elevated
glucose in GDM, but the relationship is complex, and an individual’s risk is modified by interrelated
factors, including maternal weight [1,2], gestational weight gain [3], and ethnicity [4]. Accumulating
empirical data suggests this phenotypic heterogeneity may be explained by multiple physiologic defects,
demonstrable on sophisticated laboratory insulin secretion and sensitivity testing [5,6]. As a result of
this heterogeneity, there is a continuum and breadth in the risk of pregnancy complications associated
with contemporary definitions for this condition [7,8]. Therefore, for GDM, like in much of healthcare,
there is a need to move from the current one-size-fits-all approach towards a personalised and
risk-stratified model-of-care.
A personalised approach would stratify women with GDM by the estimated risk of pregnancy
complications. Those at high risk would maximally benefit from the targeted delivery of evidence-based
preventative and therapeutic interventions. Those at low risk would be spared unnecessary treatment
and may be offered less intensive intervention. Accurate risk prediction models working within
existing diagnostic definitions and utilising predictors readily available in routine care, could be
implementable in clinical care and would be feasible and scalable. From a public health perspective,
this could enable a risk-stratified approach and development of new models of care to better allocate
scarce healthcare resources, imperative in the context of the increasing GDM prevalence [9–12].
Stratifying affected women by their risk of pregnancy complications requires a method to
estimate the absolute risk of future events in an individual based on readily available characteristics,
or a prediction model. Many fields of medicine have seen rapid growth in the development of
prediction models. However, such models are rarely translated to clinical practice [13,14], and hence
rarely positively influence patient care as their creators intended. A systematic review was conducted
to establish the existing literature and inform progress towards optimal primary research in prediction
modelling [15] and its translation into clinical care.
The aims of this systematic review were to: identify prognostic prediction models for pregnancy
complications in women with GDM; describe characteristics of the identified prognostic prediction models
qualitatively; compare the performance of identified prognostic prediction models quantitatively, with
meta-analysis if appropriate, and critically assess the conduct and reporting of prediction modelling
development methods.
2. Materials and Methods
A detailed description of the methods is available in the published protocol [16]. In summary,
a systematic review of prediction modelling studies for pregnancy complications in women with GDM
was conducted to identify all prediction models relevant to developing a risk-stratified approach to
GDM. A sensitive search strategy was developed combining the Ingui filter for prediction modelling
studies [17] as updated by Geersing [18] with keywords and subject headings for gestational diabetes
and relevant pregnancy complications (Supplementary Table S1). A search of MEDLINE and Embase
from inception to 16 August 2019 was executed. No limits on publication date nor language were
applied. Study selection, data extraction and critical appraisal were conducted independently by
two reviewers. Data extraction was conducted with guidance from the CHARMS checklist (checklist
for critical appraisal and data extraction for systematic reviews of prediction modelling studies) [19].
Critical appraisal focusing on the risk of bias and concerns regarding applicability was conducted
using the Prediction model Risk Of Bias overdiagnosis Tool (PROBAST) [20]. The systematic review
protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO),
number CRD42019115223.
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3. Results
3.1. Study Selection
The search returned 12,161 unique records. Following title and abstract screening, the full text
of 63 articles were assessed. Five studies meeting the selection criteria were included in this review
(Figure 1) [21–25].
Figure 1. Flow diagram of the identification, screening and eligibility assessment of the literature for
prediction models for pregnancy complications in women with gestational diabetes.
3.2. Study Characteristics
The five included studies reported the development of ten prediction models for pregnancy
complications in women with GDM (Table 1). No validation studies were identified. The composition of
the pregnancy complications predicted varied across the studies. Four studies reported the development
of a single prediction model [22–25]. One study reported the development of six models, one for each
of the six outcomes (primary caesarean delivery, birth injury, large-for-gestational-age (LGA), adiposity,
hyperinsulinaemia, hypoglycaemia) [21]. In this review, these six models are presented collectively
due to the shared model development process and methodological characteristics.
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Table 1. The ten models developed by the five prediction modelling studies for pregnancy complications
in women with gestational diabetes.
Study Type of PredictionModelling Study Model(s)
McIntyre et al. [21] Development
A. A risk engine relating maternal glycaemia and body mass
index to pregnancy outcomes with a model developed for each of:






Park et al. [22] Development B. Screening tool for predicting adverse outcomes a of GDM
Phaloprakarn and
Tangjitgamol [23] Development
C. A risk score based on clinical characteristics of GDM women
for the development of preeclampsia
Pintaudi et al. [24] Development D. Subgroups at different risks of developing the compositeadverse neonatal outcome b by RECPAM analysis
Tomlinson et al. [25] Development E. The fetal overgrowth index
Abbreviations: GDM, gestational diabetes; RECPAM, RECursive Partitioning and Amalgamation; a Adverse
outcomes were neonatal hypoglycaemia, hyperbilirubinemia, and hyperinsulinemia; admission to the neonatal
intensive care unit; large-for-gestational age; gestational insulin therapy; preeclampsia; and gestational hypertension;
b Neonatal adverse outcomes were fetal growth large or small for gestational age, mortality (neonatal deaths and
stillbirths), malformations, shoulder dystocia, neonatal intensive care unit need, hypoglycaemia, hypocalcaemia,
hyperbilirubinemia, and respiratory distress syndrome.
3.3. Characteristics of the Models
3.3.1. Source of Data and Participants
Four prediction modelling studies had a retrospective study design using routinely collected data,
three from a single centre [22,23,25] and one from multiple centres [24] (Table 2). One prediction modelling
study used a historical cohort from a single centre of a multi-centre prospective observational study [21].
The study populations varied across studies (Table 3). Two studies included only women with
GDM [23,24] while three also included women without GDM [21,22,25]. Diagnostic criteria for GDM
varied by region. Uniquely, one study was a post hoc analysis of a historical cohort where participants
and clinicians were blinded to oral glucose tolerance test (OGTT) results [21]. Hence, in this study,
10.5% of participants who would meet the International Association of Diabetes in Pregnancy Study
Groups diagnostic criteria for GDM, did not receive any specific treatment for this condition. In the
other studies, treatment for GDM followed a standardised institutional protocol [23–25] or was not
reported [22].
Exclusion criteria were comparable across studies with the exception of the prospective
observational study with blinded OGTT results [21] (Table 3). This study had more extensive exclusion
criteria to reduce the likelihood of non-adherence to the study protocol. This prediction modelling study
also excluded participants with missing data for predictors and those with non-Caucasian ethnicity.
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Table 2. Source of data and characteristics of studies used to develop models for pregnancy complications in women with gestational diabetes.
Model Source of Data Study Setting Study Dates Sample Size
A risk engine relating maternal





The antenatal clinic, Mater Misericordiae
Mothers’ Hospital, Australia
Jul 2000–
Apr 2006 n = 1248
Screening tool for predicting adverse
outcomes of GDM [22] Retrospective cohort
Single centre





(306 in GDM group)
A risk score based on clinical
characteristics of GDM women for






Feb 2008 n = 813
Subgroups at different risks of







May 2015 n = 2736
The fetal overgrowth index [25] Retrospective cohort
Single centre
Collaborative diabetes in pregnancy
program, South Shore Hospital, USA
Mar 2010–
May 2012 n = 275
Abbreviation: GDM, gestational diabetes.
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Table 3. Clinical characteristics of the study populations used to develop models for pregnancy complications in women with gestational diabetes.
Models Inclusion Criteria Exclusion Criteria Nulliparous Ethnicity Diagnostic CriteriaUsed For GDM Treatment Status
A risk engine relating
maternal glycaemia and





Multiple pregnancy, stillbirth, congenital
anomaly, non-Caucasian mother, birth < 33
weeks gestation, missing data for key
independent variables, age ≤ 18 years,
uncertainty of gestational age, inability to
complete oral glucose-tolerance test within 32
weeks gestation, assisted conception, previous
diabetes requiring pharmacologic treatment or
infection with hepatitis B or C virus
54.5% 100% Caucasian
NA (Participants








outcomes of GDM [22]
Two groups: 1)




Multiple pregnancy, pre-gestational diabetes,
diagnosis with GDM at <24 weeks gestation,
anomalous foetuses, chronic hypertension
NR NR Universal screeningwith ACOG approach b
Treatment not
reported
A risk score based on
clinical characteristics of
GDM women for the
development of
preeclampsia [23]









risks of developing the
composite adverse
neonatal outcome [24]
















Abbreviations: GDM, gestational diabetes; HAPO, Hyperglycaemic and adverse pregnancy outcomes; IADPSG, International Association of Diabetes in Pregnancy Study Groups; NA, not
applicable; OGTT, oral glucose tolerance test; NR, not reported; ACOG, American College of Obstetricians and Gynaecologists; a The HAPO study [26] included all pregnant women unless
they had one or more exclusion criteria listed above; b ACOG approach = two-step procedure using a screening 50 g glucose challenge test (GCT) with abnormal ≥ 140 mg/dL (7.8 mmol/L)
and diagnostic 100 g 3 h oral glucose tolerance test (OGTT) with two or more values above the Carpenter-Coustan cut-offs [27] considered abnormal (≥ 95 mg/dL [5.3 mmol/L] at baseline,
≥ 180 mg/dL [10.0 mmol/L] after 1 h post-load, ≥ 155 mg/dL [8.6 mmol/L] after 2 h post-load, ≥ 140 mg/dL [7.8 mmol/L] after 3 h post-load) [28]; c IADPSG approach = risk factor-based
screening with a 75 g 2 h OGTT with one or more values above the IADPSG cut-offs considered abnormal (≥ 92 mg/dL [5.1 mmol/L] at baseline, ≥ 180 mg/dL [10.0 mmol/L] at 1 h post-load,
≥ 153 mg/dL [8.5 mmol/L] at 2 h post-load) [29].
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3.3.2. Outcome(s) to be Predicted
The pregnancy complications for prediction in women with GDM varied across studies (Table 4
and Figure 2).
Figure 2. Outcome(s) to be predicted by studies for pregnancy complications in women with
gestational diabetes.
The most common outcome to be predicted was the delivery of an LGA neonate, as it was included
as an outcome in four of the five prediction modelling studies (Table 4 and Figure 2). In these four
studies, LGA was defined as greater than the 90th percentile by gestational age. However, there was
variation in the methods of standardization, with one study adjusting for maternal height and weight,
ethnicity and parity [25] and the others adjusting for fetal sex and parity [24], fetal sex and ethnicity [22]
or fetal sex alone [21]. Two of these studies included LGA neonates within a composite [22,24], it was
handled as a single outcome in another study [21], and was a sole outcome for another [25].
Neonatal hypoglycaemia was selected as an outcome in three studies. It was defined as blood
glucose < 2.2 mmol/L universally, however, there were variations in the timing of measures and mode
of measurement were not defined in two studies [21,24]. Neonatal hyperinsulinaemia was selected as
an outcome in two studies, defined as an elevated cord c-peptide level in one study [21] and as an
elevated neonatal serum insulin measure in the other [24].
Two models predicted a composite outcome [22,24]. The first predicted a composite for adverse
outcomes affecting both the mother and neonate [22]. The prediction of the second was limited to
complications affecting the neonate [24]. However, this composite was more extensive, including
11 outcomes. Similar pregnancy complications were the subject of a third prediction modelling study,
however here the outcomes were predicted in six discrete models for a single outcome rather than as a
composite [21].
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Table 4. Outcome(s) to be predicted and candidate predictors in models for pregnancy complications in women with gestational diabetes.
Model
Outcome(s) to Be Predicted Candidate Predictors Events per
PredictorType Event Number of Events Number Type
A risk engine relating maternal




(1) primary caesarean delivery 241
NR NR
–
(2) birth injury (including shoulder dystocia) 29 –
(3) LGA 175 –
(4) neonatal adiposity 100 –
(5) neonatal hyperinsulinemia 76 –
(6) neonatal hypoglycaemia 73 –
Screening tool for predicting
adverse outcomes of GDM [22] Composite
“adverse outcomes of GDM”: neonatal
hypoglycaemia, hyperbilirubinemia,
and hyperinsulinemia; admission to the








A risk score based on clinical
characteristics of GDM women
for the development of
preeclampsia [23]







Subgroups at different risks of
developing the composite
adverse neonatal outcome [24]
Composite
“neonatal adverse outcome”: fetal growth
large or small for gestational age, mortality
(neonatal deaths and stillbirths),
















Abbreviations: GDM, gestational diabetes; LGA, large-for-gestational age; NICU, neonatal intensive care unit; NR = not reported; a Calculated for the entire study population rather than
the GDM only group.
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3.3.3. Candidate Predictors
The number of candidate predictors investigated ranged from seven to 24 (Table 4). A variety
of candidate predictors were chosen for model development with a tendency towards those that
are routinely available in clinical practice via patient history or physical examination, or glycaemic
measures available routinely via diagnostic testing for GDM. One study considered predictors from
investigations that may not be available in routine care in all settings, serum analytes (first-trimester
pregnancy-associated plasma protein A and second-trimester total human chorionic gonadotropin and
inhibin-A serum) and fetal abdominal circumference from an obstetric ultrasound performed between
24 and 30 weeks gestation [25].
3.3.4. Model Development
The presence and handling of missing data were not adequately reported in the four studies
utilising routinely collected data [22–25] (Supplementary Table S2).
Statistical power varied across the studies, from two to 106 events per predictor (Table 4 and
Figure 3).
Figure 3. Events per predictor for prediction modelling studies for pregnancy complications in women
with GDM. The events per predictor (EPP) are shown, where A indicates the EPP for Pintaudi et al. [24];
B, Park et al. [22]; C, Phaloprakarn and Tangjitgamol [23]; D, Tomlinson et al. [25]. The EPP could
not be calculated for McIntyre et al. [21] An EPP above 10 to 20 is regarded as the minimum sample
size for model development [19]. This graphical presentation format was adapted from Ensor and
colleagues [30].
Multivariable logistic regression was the most commonly used modelling method, described
in four studies [21–23,25]. Notably, a tree-based approach, namely the recursive partitioning and
amalgamation (RECPAM) method, was used in one study (Supplementary Table S2) [24]. In this study
a binary decision-tree that uses answers from a series of yes/no questions about clinical characteristics
was developed to predict an individual’s likely outcome. Continuous predictors were dichotomised
using cut-points fitted to the development data in two studies [24,25]. Methods for the selection of
predictors for inclusion in and during multivariable modelling varied across the studies (Supplementary
Table S2).
3.3.5. Predictors Selected in the Final Models
Ten predictors were selected for the final models across the five studies (Table 5 and Figure 4).
Some measure of glycaemia and BMI was included in the final models of four of the five studies.
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Table 5. The selected predictors, presentation format and performance of models for pregnancy complications in women with gestational diabetes.
Model Selected Predictors Presentation Format Evaluation
Performance
Calibration Discrimination (c-statistic a [95% CI])
A risk engine relating maternal
glycaemia and body mass index to
pregnancy outcomes b [21]
Fasting, one hour, two hour
OGTT results c, age, height, BMI






Primary caesarean delivery: 0.694 (0.661–0.727)





Screening tool for predicting adverse
outcomes of GDM [22]
BMI at time of diagnosis, fasting





(apparent) GOF (p = 0.27) 0.642 (NR)
A risk score based on clinical
characteristics of GDM women for
the development of preeclampsia [23]
First trimester BMI ≥ 27 kg/m2,
GDM diagnosed within 20 weeks
of gestation, poor glycaemic
control e
Simplified scoring system Internal validation(apparent) GOF (p = 0.792) 0.911 (0.877–0.946)
Subgroups at different risks of








The fetal overgrowth index [25]
High fasting glucose f, enlarged
abdominal circumference g,
excessive weight gain h, history
of macrosomia i, Age ≤ 30
Simplified scoring system Internal validation(bootstrapping) NR 0.89 (0.888–0.891)
Abbreviations: c-statistic, concordance statistic; CI, confidence interval, BMI, body mass index; GDM, gestational diabetes; GOF, goodness of fit; LGA, large-for-gestational-age; NR, not
reported; OGTT, oral glucose tolerance test; a The concordance statistic is equal to the area under the receiver operating characteristic curve for models predicting binary outcomes;
b This study presented results for each of eight fixed sets of predictors (designated models A to H) from the following: fasting, 1-hour post-load (1 h) and 2-hour post-load (2 h) OGTT
results, haemoglobin A1c, age, height, BMI at time of OGTT (24–32 weeks gestation) and parity. Six of the eight sets of predictors (Models A to F) only included glycaemic measures as
predictors—fasting, 1 h and 2 h glucose levels from an OGTT in varying combinations or averaged, or haemoglobin A1c. Two sets of predictors (Models G and H) combined four clinical
characteristics (age, height, BMI and parity) with OGTT results, as individual components or averaged respectively. Of the eight sets of predictors evaluated the authors nominated model
G (individual OGTT components with clinical characteristics) as having the best predictive ability and presented the models using this set of predictors most completely, reporting
standardised coefficients for each. Hence, for comparison, we considered these models to represent the “final” model in their development process and hence, it is these results that are
presented; c Results from a 75 g, 2-hour OGTT undertaken at 24 to 32 weeks gestation; d Results from a 100 g, 3-hour OGTT undertaken at 24 to 28 weeks gestation; e Poor glycaemic control
defined as ≥ 2 separate occasions of fasting glucose ≥ 5.8 mmol/L and/or 2 postprandial glucose ≥ 6.7 mmol/L after GDM treatment; f High fasting glucose defined as fasting glucose at
24 to 30 weeks (either serum value derived from OGTT or mean fasting capillary blood glucose over 1 week) ≥ 5.6 mmol/L (100 mg/dL); g Enlarged abdominal circumference defined as
≥ 90th percentile on ultrasound between 24 and 30 weeks; h Excessive weight gain defined as weight gain in second and third trimester ≥ 0.3 lb/week above the Institute of Medicine
(BMI-based) goal range; i History of macrosomia defined as prior infant birthweight > 4 kg.
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Figure 4. Selected predictors in final models for pregnancy complications in women with
gestational diabetes.
3.3.6. Model Evaluation
Model performance was evaluated using the same dataset used to develop the model (apparent
validation) in all but one study [25] (Table 5). In this study, results of internal validation based on
resampling of the development dataset using bootstrapping was reported. No studies reported results
of external validation as a measure of transportability of the developed model to new populations.
3.3.7. Model Presentation
Three studies [23–25] included an alternative presentation format of the final models designed for
ease of use and clinical application (Table 5).
3.4. Comparison of Predictive Performance
Model performance was most commonly reported in terms of discrimination with four of the
studies reporting a concordance statistic (c-statistic) for their final models [21–23,25]. For these
four models predicting a binary outcome, the c-statistic is equal to the area under the receiver
operating characteristic (ROC) curve (AUC) and ranged from 0.517 to 0.911 (Table 5). Two studies
reported that calibration was adequate, presenting non-significant findings for the Hosmer–Lemeshow
goodness-of-fit test [22,23]. A meta-analysis of performance measures was not appropriate because
the model development studies were not sufficiently homogenous with regard to the outcome to be
predicted and no validation studies for a common prediction model were identified.
Four studies reported classification measures: sensitivity and specificity and/or positive and
negative predictive values [21–23,25]. Cut-points were not determined a priori. In two studies
they were determined by selecting a point on the ROC curve closest to the upper left corner, which
maximises the Youden index [21,22]. The method for determination was not specified in the other two
studies [23,25].
3.5. Risk of Bias and Concerns Regarding the Applicability of Models
As assessed using the PROBAST tool [20], all models had a high risk of bias driven by the analysis
domain (Figure 5 and Supplementary Table S3). There was a high concern regarding the applicability
of two studies to the systematic review question [21,22], as only a minority of the participants were
affected by GDM. Moreover, in one of these studies [21], the exclusion of non-Caucasian women and
women with a history of gestational diabetes requiring pharmacologic treatment may further limit
its applicability.
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Figure 5. The risk of bias and concern regarding the applicability of the models developed in the five
prediction modelling studies for pregnancy complications in women with gestational diabetes using
the Prediction model Risk of Bias Assessment Tool (PROBAST). The x-axes display the proportion of
studies rated by level of concern (low, high or unclear) for risk of bias or applicability for each domain.
4. Discussion
This systematic review identified five prediction modelling studies for pregnancy complications in
women with GDM. Approaches to prediction varied, but the birth of an LGA neonate was the leading
outcome, whether as part of a composite or singularly. Models seeking to predict a single outcome
were more discriminatory than those predicting a composite outcome. Three predictors emerged in
most models: glycaemic measures, BMI, and maternal age. Predictive performance was generally
inadequately reported, and external validation was lacking. All models had a high risk of bias due to
methodologic limitations in analysis as assessed by PROBAST.
4.1. Models Identified
Ten prediction models were developed by five prediction modelling studies, reflecting five distinct
approaches to the clinical problem of quantifying the absolute risk of pregnancy complications in
women with GDM. The literature is relatively lacking, compared to the related, but distinct literature
on diagnostic prediction models for the development of GDM, with 17 models identified in a recent
review [31]. However, interest in prognostic-based approaches to pregnancy risks in GDM is growing,
with the first model published ten years ago and the later four within the last three years.
The model developed using a prospective cohort utilised an unselected population of pregnant
women, of which 10.5% would meet current diagnostic criteria for GDM [21]. We acknowledge that
the population in this prediction modelling study may not strictly meet the population criteria for
eligibility of this review. However, we believe that the omission of this study would limit the value of
this review, given its robust prospective study design and unique treatment-naïve study population.
Furthermore, recognising that there is a continuum of risk for pregnancy complications related to GDM,
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this study is valuable because it facilitates feasibility assessment for a prediction model for pregnancy
complications in women with hyperglycaemia independent of the consensus-based International
Association of Diabetes and Pregnancy Study Group diagnostic threshold for GDM.
A recent prediction modelling study conducted by Barnes and colleagues [32] featured prominently
at the title and abstract screening stage as it seemed to be especially applicable to the review question.
This study developed and externally validated a model to predict the need for insulin therapy in women
with GDM. Following model development, a post-hoc analysis found that the outcome of this model,
the need for insulin therapy, was strongly associated with pregnancy complications. As pregnancy
complication, the outcome of interest for this review was not the subject of this prediction modelling
study it was ultimately excluded. We, however, note the close relationship of these outcomes and the
relevance of this existing prediction modelling study to the overarching aim of developing a stratified
model-of-care for women with GDM.
4.2. Characteristics of the Models
4.2.1. Outcome(s) to Be Predicted
The delivery of an LGA neonate was the most common outcome predicted, offering three key
advantages. Firstly, it reflects the classical maternal hyperglycaemia-fetal hyperinsulinaemia hypothesis,
linking maternal hyperglycaemia to the LGA neonate, via transplacental glucose transport causing
secondary fetal hyperinsulinaemia [33]. Secondly, although potentially too simplistic, excessive fetal
growth is the unifying feature linking GDM to downstream pregnancy complications, such as failure to
progress in labour, obstetric intervention, and shoulder dystocia. Thirdly, an LGA neonate with excess
neonatal adiposity has poorer long-term metabolic health [34–38], with potential inter-generational
implications [39].
Where multiple outcomes are potentially relevant, the prediction of a composite outcome, as in two
of the models [22,24], may more accurately quantify multiple risks that concern women and clinicians
and may be more translatable into clinical practice than a model predicting a single outcome. However,
a poorly constructed composite outcome may be confusing and limit clinical application. Future model
development should provide a clear rationale for the use and formulation of composite outcomes.
There may be utility in heeding recommendations that the components of composite outcomes: (1) are
of similar importance, (2) occur with similar frequency, and (3) are likely to have similar relative risk
reductions (or predictive effects moving in the same direction) with similar underlying biology [40].
4.2.2. Model Development
Two studies were inadequately powered with less than 10 events per predictor (EPP) [23,25] (Table 4
and Figure 3), generating significant risks for overfitting and consequently biased predictions [19].
The two studies which predicted composite outcome [22,24] were adequately powered for model
development with more than twenty EPP [19]. This is an advantage of composite outcomes where event
rates are low (Figure 4). The EPP for the six models developed in one study could not be calculated
as the candidate predictors were not reported [21]. Although an EPP above 10–20 is traditionally
advocated as the minimum sample size for model development [19], future studies should consider the
recent proposal that a tailored sample size estimate may be advantageous in certain circumstances [41].
The dichotomisation of continuous predictor variables leads to substantial loss of information
and is widely discouraged [42–45]. This is an inherent disadvantage of tree-based models included in
this review [24] and was also notable in the model developed using classical regression methods [25].
In both models, continuous predictor variables were dichotomised using data-driven cut points, leading
to high risks of bias [46]. In two models, continuous variables were dichotomised using cut-points
which were pre-defined and independent to the development data [21,23], which leads to the loss of
information but minimises the risk of bias. Continuous predictors were only handled optimally in one
study [22]. Future model development studies should avoid dichotomising continuous predictors.
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Selection of predictors is a key component of the model building at two stages, 1) inclusion in
modelling and 2) during multivariable modelling. Where selection is based on associations with the
outcome in the development dataset, there is a high risk that the developed model will be overfitted
to this dataset. This was observed in three studies [22,23,25] and was inadequately reported in the
other two [21,24]. In future studies, model generalisability may be improved by a priori selection of
predictors for inclusion or selection independent of the predictor–outcome association, such as those
based on clinical expertise [47].
4.2.3. Predictors Selected in the Final Model
The predictors most commonly selected in final models, glycaemic measures (n = 4), BMI (n = 4),
and age (n = 2) are routinely available in clinical practice. These predictors should be included in the
set of candidate predictors evaluated in future model development studies.
4.2.4. Model Evaluation
Model evaluation addresses two questions pivotal for the application of prediction models into
clinical practice: (1) how accurate are its predictions and (2) how generalisable is it [48]. Accuracy relates
to a model’s internal validity or “reproducibility” [45]. Internal validation techniques include apparent
or bootstrap validation. Generalisability considers how well the model is likely to perform in a new
but related population. It relates to a model’s external validity or transportability, tested by evaluating
the model in a new population (external validation) [45]. External validation measures predictive
performance and corrects internal validation for the inherent optimism of a model being overfitted to
the development dataset. As such, it provides a more realistic measure of predictive performance and
quantifies the “transportability” of a model to other populations. No studies identified here reported
external validation.
Three studies reported measures of model performance using apparent validation [21–23]. Here
model performance is evaluated against the sample from which it was developed. The utility is limited,
as performance is biased towards overestimating model performance in new populations. This risk of
bias is further exaggerated with the small development datasets noted here.
One reviewed study assessed internal validity using simple bootstrapping validation, with the
model repeatedly fitted to 1000 bootstrap samples and the average area under the ROC calculated
as an estimate of future performance of the model in other populations [25]. This technique for
internal validation is preferable to apparent validation conducted in the other studies, with less
biased performance estimates. It is also preferable to split-sample validation, as data available for
development and validation are maximised. Ultimately, however, external validation is essential to
establish the confidence in a model required for clinical application.
The included studies did not report any formal evaluation of the clinical usefulness of the
developed models. This could include the net-benefit realised by using the model’s predictions to
guide clinical decision-making [49]. Future studies may consider decision curve analysis [50] to
quantify the clinical value of developed models as is increasingly reported in the literature [51] and
recommended [52–54].
4.2.5. Model Presentation
A clinical prediction model is developed with the overarching premise to be applied to clinical
care to improve outcomes. Hence, developed models should be presented in a format fit for this
purpose [55]. Two studies presented simplified scoring systems [23,25], and one presented a simple
decision tree [24], all readily applicable to clinical care. The other studies reported regression coefficients
for included predictors but did not present baseline components or regression equations [21,22], and as
such do not facilitate the clinical application of the models reported.
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4.3. Comparison of Predictive Performance
The overall performance of prediction models is traditionally quantified with two essential
measures of predictive performance: discrimination and calibration [49]. Consistent with general
prediction model literature [48], performance was incompletely evaluated in prediction models
identified in this review (Table 5). Where reported, discrimination was evaluated using the c-statistic and
was graphically presented with ROC curves. Calibration was evaluated using the Hosmer–Lemeshow
goodness of fit test.
Discrimination was highest for models predicting single outcome versus composite outcomes
overall as observed in the risk score for pre-eclampsia [23] and the fetal overgrowth index [25]. Models
with single outcomes also had minimal loss in performance when adapted into simplified clinical
tools. Discrimination was more limited with composite outcomes [22] and was not reported in
the model developed using a decision-tree for a composite of neonatal complications [24]. In the
fifth study, discrimination varied considerably for the six independent models for single pregnancy
complications [21].
Calibration was evaluated in two studies using the Hosmer–Lemeshow goodness-of-fit test,
suggesting an agreement between predicted and observed probabilities [22,23]. However, this method
alone does not capture the magnitude or direction of miscalibration, limiting clinical utility. For instance,
a model with accurate predictions in the intermediate risk range, can consistently overestimate in
the low-risk range and underestimate in the high-risk range, limiting clinical usefulness. Another
limitation of the Hosmer–Lemeshow test is that it is strongly related to sample size and is usually
non-significant for small data sets, and conversely significant for large data sets [46]. Future work
should ideally report calibration graphically (calibration plot) or in a tabular format, comparing
predicted probabilities to observed outcome frequencies, and allowing the model’s performance to be
assessed at clinically relevant risk ranges [46,56].
4.4. Risk of Bias and Concerns Regarding the Applicability of Models
4.4.1. Risk of Bias
Collectively, the high risk of bias for prognostic prediction models for women with GDM limits
generalisability (Figure 5 and Supplementary Table S3), driven by analysis methods and overfitting
of models to development datasets. This is reflective of the rapid evolution of prediction modelling
methodology. The risk of bias of future prediction models may be reduced by addressing the findings
of this review and referring to relevant guidelines such as the TRIPOD (transparent reporting of a
multivariable prediction model for individual prognosis or diagnosis) statement [57].
4.4.2. Concerns Regarding Applicability
The applicability of identified models varied based on the participants in the development dataset
(Figure 5 and Supplementary Table S3). Two models sought to develop prediction models for pregnancy
complications as a basis for defining alternative diagnostic criteria, including women both with and
without GDM [21,22]. Their aims differed from this review, the prediction of pregnancy complications
in women with GDM limiting applicability.
4.5. Strengths and Limitations of this Review
To our knowledge, this is the first systematic review of prediction models for pregnancy
complications in GDM. Strengths of this review include rigorous methods and a sensitive search strategy
utilising standardised and validated search terms across the entirety of the two leading databases
of biomedical literature since their inception. Bias was minimised with prospective registration and
peer-reviewed publication protocol [16]. The risk of bias and applicability of included models was
systematically and objectively evaluated using PROBAST [20], a robust and for-purpose tool.
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Limitations included the inability to synthesize the quantitative characteristics of included models
due to the heterogeneity of included studies. However, the results of the systematic search support this
broad approach. We note that, despite the clinical imperative, there are only five prediction modelling
studies for pregnancy complications in GDM that met our eligibility criteria in the indexed medical
literature to date.
Finally, given the heterogeneity of this condition and the variety of diagnostic approaches currently
used, a developed model cannot be assumed to perform equally well (or poorly) in a new, but related
population. Clinical prediction modelling is an iterative multi-stage process [58]. External validation
in a range of new but related populations, both geographically and temporally, is crucial but, as this
review suggests, frequently neglected. Such external validation may facilitate model updating which,
by addressing the characteristics of the local population and clinical practice, is likely to optimise
model performance [59].
5. Conclusions
This review demonstrates the potential for prediction models to provide an individualised absolute
risk of pregnancy complications for women affected by GDM. However, limitations in current models
have been identified and this emphasises that future model development and validation would benefit
from the application of methodologic advances in this rapidly evolving field. External validation,
including appropriate reporting of calibration and formal evaluation of clinical usefulness with decision
curve-analysis, will significantly assist the translation of promising statistical models into a useful
clinical tool. Such a tool would be capable of improving outcomes for women with GDM by enhancing
clinical decision-making and facilitating the stratification of affected women by their risk of pregnancy
complications, thus enabling a personalised model-of-care.
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BMI body mass index
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GDM gestational diabetes
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TRIPOD transparent reporting of a multivariable prediction model for individual prognosis or diagnosis
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